UT-34 is primarily used in research settings as a selective inhibitor of soluble epoxide hydrolase (sEH), an enzyme involved in the metabolism of epoxyeicosatrienoic acids (EETs). By inhibiting sEH, UT-34 helps maintain higher levels of EETs, which have anti-inflammatory, vasodilatory, and analgesic properties. This makes UT-34 a valuable tool in studies related to inflammatory diseases, neuropathic pain, hypertension, and cardiovascular function. It has shown potential in preclinical models for reducing pain and inflammation without the side effects commonly associated with NSAIDs or opioids. Due to its stability and potency, UT-34 is often chosen in pharmacokinetic and pharmacodynamic studies aimed at developing new therapeutic agents targeting the sEH pathway.